Wild Bioscience Ltd

Wild Bioscience Ltd, based in the UK, specializes in developing innovative agricultural solutions through biotechnology and artificial intelligence to enhance crop resilience and productivity. Founded in 2021 in Oxfordshire, UK, co-founded by Dr Ross Hendron and Prof. Steve Kelly, Wild Bioscience Ltd develops advanced crop solutions through biotechnology. The company has completed series A round in which it raised GBP 45 million from investors, including Braavos Investment Advisers, Oxford Sciences Enterprises, and the University of Oxford.

The founder's history is not available, and there is no information about previous companies founded by individuals or any subsidiaries. Wild Bioscience Ltd focuses on creating next-generation resilient crops that utilize biotechnology and artificial intelligence to improve agricultural productivity. Their flagship offerings include genetically optimized crops designed for higher yields with reduced environmental impact. The company employs advanced machine learning and insights from evolutionary biology to support initiatives like food security and climate resilience.

Their innovations are deployed across markets in North America, Europe, and Asia, serving agricultural producers, food manufacturers, and sustainable farming organizations. Wild Bioscience Ltd generates revenue primarily through business-to-business (B2B) transactions with agricultural producers and food industry stakeholders. The revenue model is based on licensing agreements, partnerships with agricultural enterprises, and subscription models for ongoing support and updates to technological platforms, focusing on proprietary gene editing technologies and resilient crop varieties. Wild Bioscience Ltd plans to develop new product offerings aimed at enhancing crop resilience and productivity, with specific launch dates not disclosed.

The company intends to expand into growing markets in Asia and possibly other regions by 2025. Recent funding from its Series A round will support these initiatives, enabling the company to advance its research and development efforts in biotechnology.